News
Video
Author(s):
Delve into the exciting developments in endometrial cancer treatment, including HER2 antibody drug conjugates, checkpoint inhibitors, and the promising impact of these therapies in the quest to reduce chemotherapy use.
Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Overcoming Adversity and Achieving the American Dream in Cancer Care
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence
Mirvetuximab Soravtansine Plus Pembrolizumab Generates Reponses in pMMR FRα+ Serous Endometrial Cancer
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC